Aclaris Therapeutics, Inc.
ACRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001557746
No open-market purchases or sales by Aclaris Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $630.0M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Aclaris Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 98
- +19 vs. Q3 2024
- Shares held
- 87.5M
- +36.6M (+71.9%) vs. Q3 2024
- Total value
- $217.0M
- +$158.5M (+270.9%) vs. Q3 2024
- New holders
- 34
- 25 more added
- Sold out
- 15
- 24 more reduced
2 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ACRS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 148 | $630.0M |
| Q1 2026 | 136 | $409.4M |
| Q4 2025 | 122 | $252.1M |
| Q3 2025 | 103 | $162.8M |
| Q2 2025 | 96 | $130.4M |
| Q1 2025 | 109 | $143.8M |
| Q4 2024 | 98 | $217.0M |
| Q3 2024 | 81 | $58.5M |
| Q2 2024 | 98 | $58.1M |
| Q1 2024 | 98 | $67.5M |
| Q4 2023 | 107 | $61.4M |
| Q3 2023 | 138 | $480.0M |
| Q2 2023 | 133 | $737.2M |
| Q1 2023 | 149 | $579.3M |
| Q4 2022 | 128 | $1.04B |
| Q3 2022 | 127 | $1.00B |
| Q2 2022 | 115 | $883.3M |
| Q1 2022 | 110 | $1.02B |
| Q4 2021 | 133 | $814.9M |
| Q3 2021 | 126 | $1.02B |
| Q2 2021 | 128 | $983.4M |
| Q1 2021 | 97 | $1.14B |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Aclaris Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 0 | $0 | 0.00% | −264,377−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −255,032−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −90,000−100.0% | Sold out |
| BBR Partners, LLC | 0 | $0 | 0.00% | −60,000−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −33,183−100.0% | Sold out |
| Shay Capital LLC | 0 | $0 | 0.00% | −27,000−100.0% | Sold out |
| Algert Global LLC | 0 | $0 | 0.00% | −19,770−100.0% | Sold out |
| China Universal Asset Management Co., Ltd. | 0 | $0 | 0.00% | −13,722−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −10,740−100.0% | Sold out |
| Mirae Asset Global Investments Co., Ltd. | 0 | $0 | 0.00% | −2,580−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −1,632−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −248−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| AJOVista, LLC | – | – | – | – | Not filed |
| Halpern Financial, Inc. | – | – | – | – | Not filed |